We are live on ! Find out more
ADIL

Adial Pharmaceuticals
ADIL

8 hedge funds and large institutions have $158K invested in Adial Pharmaceuticals in 2023 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 0 increasing their positions, 2 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

0.17% more ownership

Funds ownership: 0.01% → 0.19% (+0.17%)

58% less funds holding

Funds holding: 19 → 8 (-11)

67% less capital invested

Capital invested by funds: $477K → $158K (-$319K)

85% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 13

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 2

Holders
8
Holders Change
-11
Holders Change %
-57.89%
% of All Funds
0.13%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
–
Reduced
2
Closed
13
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
UBS Group
UBS Group
Switzerland
+$2.6K
2
AWM
Abound Wealth Management
Tennessee
+$118

Top Sellers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
-$42.3K
2
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$37.5K
3
Geode Capital Management
Geode Capital Management
Massachusetts
-$28.6K
4
Renaissance Technologies
Renaissance Technologies
New York
-$22K
5
State Street
State Street
Massachusetts
-$10.9K
Name Holding Trade Value Shares
Change 		Change in
Stake
MCM
1
Manchester Capital Management
Vermont
$134K – – –
BlackRock
2
BlackRock
New York
$21.2K -$590 -5 -2%
Osaic Holdings
3
Osaic Holdings
Arizona
$1.71K -$1.53K -13 -34%
UBS Group
4
UBS Group
Switzerland
$1.52K +$2.6K +22 New
AWM
5
Abound Wealth Management
Tennessee
$76 +$118 +1 New
Morgan Stanley
6
Morgan Stanley
New York
$58 – – –
Wells Fargo
7
Wells Fargo
California
$22 – – –
Qube Research & Technologies (QRT)
8
Qube Research & Technologies (QRT)
United Kingdom
$21 – – –
Vanguard Group
9
Vanguard Group
Pennsylvania
– -$42.3K -325 Closed
Susquehanna International Group
10
Susquehanna International Group
Pennsylvania
– -$37.5K -288 Closed
Geode Capital Management
11
Geode Capital Management
Massachusetts
– -$28.6K -220 Closed
Renaissance Technologies
12
Renaissance Technologies
New York
– -$22K -171 Closed
State Street
13
State Street
Massachusetts
– -$10.9K -84 Closed
Commonwealth Equity Services
14
Commonwealth Equity Services
Massachusetts
– -$8K -58 Closed
Truist Financial
15
Truist Financial
North Carolina
– -$7.05K -54 Closed
Northern Trust
16
Northern Trust
Illinois
– -$6.18K -48 Closed
VF
17
Virtu Financial
New York
– -$6K -42 Closed
TSS
18
Two Sigma Securities
New York
– -$4.31K -33 Closed
Two Sigma Investments
19
Two Sigma Investments
New York
– -$3.67K -28 Closed
Envestnet Asset Management
20
Envestnet Asset Management
Illinois
– -$2.73K -21 Closed
Creative Planning
21
Creative Planning
Kansas
– -$2.08K -16 Closed

ADIL Hedge Fund Activity: Q3 2023 in Review

8 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Adial Pharmaceuticals (ADIL) for Q3 2023, worth a combined $158K — down 67% from $477K a quarter earlier.

Sellers outnumbered buyers: 13 funds closed out of ADIL and 2 opened new positions — a net loss of 11 holders — while 2 trimmed existing stakes and 0 added.

The largest buyer was UBS Group, opening a new position worth an estimated $2.6K. The largest seller was Vanguard Group, exiting entirely with an estimated $42.3K sold.

  • 8 institutional investors held Adial Pharmaceuticals (ADIL) as of Q3 2023, down from 19 in Q2 2023.
  • Funds reported $158K of Adial Pharmaceuticals stock for Q3 2023, down 67% quarter-over-quarter.
  • 2 funds opened new Adial Pharmaceuticals positions in Q3 2023 and 13 closed out, a net change of -11 holders.
  • The largest Adial Pharmaceuticals buyer in Q3 2023 was UBS Group, an estimated $2.6K added.
  • The largest Adial Pharmaceuticals seller in Q3 2023 was Vanguard Group, an estimated $42.3K sold.

Based on aggregated 13F filings for Q3 2023.